SCHEMBL20948833

SCHEMBL20948833

CNc1ncc(-c2ccc3cnc(NC(=O)C4CCNCC4)nc3c2)s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 13/20 0.73
GSK3B P49841 12/20 0.73
WNT1 P04628 8/20 0.73
MKNK1 Q9BUB5 2/20 0.43
BRAF P15056 2/20 0.43
ABL1 P00519 3/20 0.42
CDK2 P24941 2/20 0.41
CDK7 P50613 2/20 0.41
CDK9 P50750 2/20 0.41
CIT O14578 1/20 0.41
CASK O14936 1/20 0.41
AURKA O14965 1/20 0.41
GAK O14976 1/20 0.41
DCLK1 O15075 1/20 0.41
MAP3K7 O43318 1/20 0.41
CCNT1 O60563 1/20 0.41
ULK1 O75385 1/20 0.41
RPS6KA5 O75582 1/20 0.41
PAK3 O75914 1/20 0.41
CDKL5 O76039 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20950085 0.89 DYRK1A (0.74) DYRK1AGSK3BWNT1MKNK1MAP4K1
SCHEMBL30005459 0.84 DYRK1A (1.00) DYRK1AGSK3BWNT1ABL1
SCHEMBL19516218 0.84 DYRK1A (1.00) DYRK1AGSK3BWNT1ABL1
SCHEMBL20951022 0.82 DYRK1A (0.71) DYRK1AGSK3BWNT1ABL1CLK2
SCHEMBL20948714 0.81 DYRK1A (0.76) DYRK1AGSK3BWNT1MKNK1ABL1
SCHEMBL20951288 0.80 GSK3B (0.72) DYRK1AGSK3BWNT1
SCHEMBL20951176 0.78 DYRK1A (0.54) DYRK1AGSK3BWNT1ABL1CLK2
SCHEMBL20951174 0.78 DYRK1A (0.54) DYRK1AGSK3BWNT1ABL1CLK2
SCHEMBL20949303 0.78 DYRK1A (0.71) DYRK1AGSK3BWNT1ABL1CLK2
SCHEMBL20950518 0.77 DYRK1A (0.58) DYRK1AGSK3BWNT1MKNK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.